{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T05:14:33Z","timestamp":1782537273617,"version":"3.54.5"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T00:00:00Z","timestamp":1629676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T00:00:00Z","timestamp":1629676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shanghai Yingli Pharmaceutical Co., Ltd."},{"name":"Biomedical Science and Technology Support Program of Shanghai Science and Technology Commission","award":["18431904700"],"award-info":[{"award-number":["18431904700"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>YY-20394, an oral phosphatidylinositol 3-kinase delta (PI3K\u03b4) inhibitor, was investigated in a first-in-human study of patients with relapsed or refractory B-cell malignancies. During dose escalation, 25 patients received 20\u2013200\u00a0mg of YY-20394 daily. The primary outcome measures were tolerability and dose-limiting toxicity (DLT). The secondary outcomes were pharmacokinetic parameters, progression-free survival (PFS) and the objective response rate (ORR). Since no patients experienced DLT, the maximum tolerated dose (MTD) was not reached. The majority (\u2265\u20095%) of drug-related adverse events were\u2009\u2265\u2009grade III, being neutropenia (44.0%), pneumonia (16.0%), hyperuricemia (12.0%), lymphocythemia (8.0%), leukopenia (8.0%) and pneumonitis (8.0%). The overall ORR was 64.0% (95% confidence interval (CI): 45.2, 82.8%) including 5 patients with complete remission (CR), 11 with partial remission (PR), 2 with stable disease (SD) and 7 with progressive disease (PD), while the disease control rate (DCR) was 72.0% (95% CI: 54.4, 89.6%). The ORR of 10 patients with follicular lymphoma was 90%. The median PFS time was 255\u00a0days. One PR patient with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) who received 40\u00a0mg q.d. had a durable response of around 36\u00a0months. The median PFS time of 10 patients with follicular lymphoma was 300\u00a0days. A recommended phase 2 dose of 80\u00a0mg q.d. was established. Considering that YY-20394 was well-tolerated with promising preliminary efficacy, further development is warranted.<\/jats:p><jats:p><jats:italic>Trial registration<\/jats:italic> clinicaltrials.gov, NCT03757000, retrospectively registered, November 28, 2018, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03757000?term=NCT03757000&amp;draw=2&amp;rank=1\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03757000?term=NCT03757000&amp;draw=2&amp;rank=1<\/jats:ext-link>.<\/jats:p>","DOI":"10.1186\/s13045-021-01140-z","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T09:21:55Z","timestamp":1629710515000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Phase 1 clinical trial of the PI3K\u03b4 inhibitor YY-20394 in patients with B-cell hematological malignancies"],"prefix":"10.1186","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct03757000","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Bo","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyuan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meifeng","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyan","family":"Ping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongliang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanying","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zusheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,23]]},"reference":[{"issue":"2","key":"1140_CR1","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1001\/jamaoncol.2019.3994","volume":"6","author":"ST Bird","year":"2020","unstructured":"Bird ST, Tian F, Flowers N, Przepiorka D, Wang R, Jung TH, et al. Idelalisib for treatment of relapsed follicular lymphoma and chronic lymphocytic leukemia: a comparison of treatment outcomes in clinical trial participants vs medicare beneficiaries. JAMA Oncol. 2020;6(2):248\u201354.","journal-title":"JAMA Oncol"},{"issue":"3","key":"1140_CR2","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1182\/blood-2016-02-702761","volume":"128","author":"CY Cheah","year":"2016","unstructured":"Cheah CY, Fowler NH. Idelalisib in the management of lymphoma. Blood. 2016;128(3):331\u20136.","journal-title":"Blood"},{"issue":"4","key":"1140_CR3","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nrclinonc.2014.42","volume":"11","author":"JA Burger","year":"2014","unstructured":"Burger JA, Okkenhaug K. Haematological cancer: idelalisib-targeting PI3K\u03b4 in patients with B-cell malignancies. Nat Rev Clin Oncol. 2014;11(4):184\u20136.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"1140_CR4","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1182\/blood-2017-05-786566","volume":"131","author":"IW Flinn","year":"2018","unstructured":"Flinn IW, O\u2019Brien S, Kahl B, Patel M, Oki Y, Foss FF, et al. Duvelisib, a novel oral dual inhibitor of PI3K-\u03b4, \u03b3, is clinically active in advanced hematologic malignancies. Blood. 2018;131(8):877\u201387.","journal-title":"Blood"},{"issue":"2","key":"1140_CR5","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1080\/10428194.2020.1832660","volume":"62","author":"M Coleman","year":"2021","unstructured":"Coleman M, Belada D, Casasnovas RO, Gressin R, Lee HP, Mehta A, et al. Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3K\u03b4 inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202). Leuk Lymphoma. 2021;62(2):368\u201376.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"1140_CR6","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1124\/jpet.120.265538","volume":"374","author":"N Shin","year":"2020","unstructured":"Shin N, Stubbs M, Koblish H, Yue EW, Soloviev M, Douty B, et al. Parsaclisib is a next-generation phosphoinositide 3-kinase \u03b4 inhibitor with reduced hepatotoxicity and potent antitumor and immunomodulatory activities in models of B-cell malignancy. J Pharmacol Exp Ther. 2020;374(1):211.","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"1140_CR7","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1093\/annonc\/mdx097","volume":"28","author":"A Younes","year":"2017","unstructured":"Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, et al. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol. 2017;28(7):1436\u201347.","journal-title":"Ann Oncol"},{"issue":"25","key":"1140_CR8","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745\u201360.","journal-title":"Blood"},{"issue":"1","key":"1140_CR9","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1182\/hematology.2020000119","volume":"2020","author":"A Hanlon","year":"2020","unstructured":"Hanlon A, Brander DM. Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors. Hematology Am Soc Hematol Educ Program. 2020;2020(1):346\u201356.","journal-title":"Hematology Am Soc Hematol Educ Program"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-021-01140-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-021-01140-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-021-01140-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T09:49:49Z","timestamp":1629712189000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-021-01140-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,23]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1140"],"URL":"https:\/\/doi.org\/10.1186\/s13045-021-01140-z","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,23]]},"assertion":[{"value":"1 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Review Boards of the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Affiliated Cancer Hospital of Peking University involved gave approval for the study protocols and all enrolled patients gave their consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Prof. Lugui Qiu and Prof. Junyuan Qi received research grants from Shanghai Yingli Pharmaceutical Co., Ltd.; Prof. Bo Jiang, Prof. Lugui Qiu, Prof. Junyuan Qi, Prof. Yuqin Song, Prof. Meifeng Tu, Prof. Lingyan Ping, Prof. Zengjun Li received consulting fees from Shanghai Yingli Pharmaceutical Co., Ltd; Dr. Zusheng Xu is a shareholder of Shanghai Yingli Pharmaceutical Co., Ltd; Dr. Hanying Bao and Mr. Zongliang Liu are employees of Shanghai Yingli Pharmaceutical Co., Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"130"}}